<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976728</url>
  </required_header>
  <id_info>
    <org_study_id>000070</org_study_id>
    <nct_id>NCT01976728</nct_id>
  </id_info>
  <brief_title>LutrePulse Hypogonadotropic Hypogonadism</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic&#xD;
      hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the&#xD;
      OmniPod pump versus placebo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation Rate</measure>
    <time_frame>From treatment Day 1 up to 4 weeks after second positive β-hCG test, approximately 9 weeks</time_frame>
    <description>Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progesterone (P4) Levels</measure>
    <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
    <description>Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>2 to 4 weeks after a second positive serum β-hCG test</time_frame>
    <description>Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Pregnancy Rate</measure>
    <time_frame>Approximately 14 days after LH surge</time_frame>
    <description>Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH Surge Detection</measure>
    <time_frame>Daily from Day 11 until first positive LH surge or until Day 39</time_frame>
    <description>Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Follicular Development: Number of Follicles With a Mean Diameter Greater Than or Equal to (≥)14 mm</measure>
    <time_frame>From treatment Day 10 to treatment Day 21</time_frame>
    <description>Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Follicular Development: Number of Dominant Follicles With a Mean Diameter of ≥18 mm</measure>
    <time_frame>From treatment Day 10 to treatment Day 21</time_frame>
    <description>Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteal Phase Support: Maximum P4 Levels</measure>
    <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
    <description>Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteal Phase Support: Mean P4 Levels</measure>
    <time_frame>Median post-dose P4 values across Treatment Days 19, 21, 23, 25, and 27</time_frame>
    <description>Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Follicle-stimulating Hormone (FSH)</measure>
    <time_frame>Baseline (pre-dose), Treatment Day 1, Treatment Day 10</time_frame>
    <description>FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LH</measure>
    <time_frame>Baseline (pre-dose), Treatment Day 1, Treatment Day 10</time_frame>
    <description>LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum FSH and LH Levels</measure>
    <time_frame>Treatment Days 1 and Day 10</time_frame>
    <description>Mean FSH and LH levels on Day 1 and Day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol (E2) Serum Levels</measure>
    <time_frame>At treatment Day 1 and Day 10</time_frame>
    <description>E2 serum levels on Day 1 and Day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, Intensity, and Frequency of Adverse Events (AEs)</measure>
    <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology, Clinical Chemistry, and Urinalysis</measure>
    <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
    <description>Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS)</measure>
    <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
    <description>Proportion of subjects reporting OHSS classified as mild, moderate, or severe.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Primary Amenorrhea With Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>LutrePulse 10 µg/pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadorelin acetate 10 µg/pulse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LutrePulse 15 µg/pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadorelin acetate 15 µg/pulse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LutrePulse 20 µg/pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadorelin acetate 20 µg/pulse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump</intervention_name>
    <arm_group_label>LutrePulse 10 µg/pulse</arm_group_label>
    <other_name>LutrePulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump</intervention_name>
    <arm_group_label>LutrePulse 15 µg/pulse</arm_group_label>
    <other_name>LutrePulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump</intervention_name>
    <arm_group_label>LutrePulse 20 µg/pulse</arm_group_label>
    <other_name>LutrePulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18-40 years old&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 38 kg/m2&#xD;
&#xD;
          -  Clinical history or recently diagnosed with primary amenorrhea with hypogonadotropic&#xD;
             hypogonadism&#xD;
&#xD;
          -  Hormonal values in a centrally analyzed fasting blood sample: FSH &lt;5 IU/L and mean LH&#xD;
             &lt;5 IU/L&#xD;
&#xD;
          -  Desire to become pregnant&#xD;
&#xD;
          -  Discontinued estrogen-progesterone replacement therapy at least 1 month before&#xD;
             screening&#xD;
&#xD;
          -  Negative progestin challenge test performed during screening&#xD;
&#xD;
          -  PAP smear within 24 months of the initial visit&#xD;
&#xD;
          -  Normal or stable CT scan or MRI scan of the hypothalamic pituitary region&#xD;
&#xD;
          -  Prolactin and thyroid-stimulating hormone (TSH) within normal clinical laboratory&#xD;
             limits&#xD;
&#xD;
          -  Male partner with normal semen analysis, including volume, liquefaction time, sperm&#xD;
             count, and motility, according to the local laboratory normal criteria, within the&#xD;
             past year&#xD;
&#xD;
          -  Normal transvaginal ultrasound at screening with respect to uterus and adnexa&#xD;
             (presence of both ovaries and tubes, without evidence of clinically significant&#xD;
             abnormality) and with normal uterine cavity and normal cervix&#xD;
&#xD;
          -  Tube patency on saline tubal perfusion, hysterosalpingography or laparoscopy on file&#xD;
             within the past 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition that may interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug&#xD;
&#xD;
          -  A history of, or currently diagnosed with clinically important cardiovascular,&#xD;
             pulmonary (e.g. serious corticosteroid-dependent asthma), gastrointestinal, hepatic,&#xD;
             metabolic, renal, endocrinological (e.g. insulin dependent diabetes mellitus), or&#xD;
             neurological (e.g. epilepsy, serious migraine, central nervous system (CNS) lesions&#xD;
             (in cases where hypogonadotropic hypogonadism is secondary to a CNS lesion or its&#xD;
             treatment) abnormality&#xD;
&#xD;
          -  A history of adrenal or uncontrolled thyroid disorders, or hyperprolactinemia&#xD;
&#xD;
          -  Prior treatment cycle with gonadotropins or GnRH within the last 2 months&#xD;
&#xD;
          -  Known allergy to study drug or its components&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
&#xD;
          -  Ovarian enlargement or cyst of unknown etiology&#xD;
&#xD;
          -  Abnormal gynecological bleeding of undetermined origin&#xD;
&#xD;
          -  Previous or current hormone-dependent tumor&#xD;
&#xD;
          -  Known active substance abuse&#xD;
&#xD;
          -  Planning to undergo in vitro fertilization procedure in the course of a study&#xD;
             treatment cycle&#xD;
&#xD;
          -  Currently undergoing treatment with gonadotropin hormones (FSH and LH), psychotropic&#xD;
             medication, sex hormones, or any other medication known to interfere with normal&#xD;
             reproductive function or that can affect GnRH secretion (e.g. neuroleptics, dopamine&#xD;
             antagonists, spironolactone, levodopa, phenothiazine, digoxin)&#xD;
&#xD;
          -  Ongoing pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fertility Treatment Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Health UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Associates of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Fertility Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Reproductive Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center-REI</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University Physicians Group</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Reproductive Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Case Medical Center, MacDonald Clinical Trials</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Reproductive Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center, Abington IVF &amp; Genetics, L.P.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Reproductive Medicine, PC</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State MS Hershey Medical Center, Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Associates of Memphis PLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Fertility Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Reproductive Medicine</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Fertility Center</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Institute for Reproductive Medicine</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive Fertility Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovo</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <results_first_submitted>January 8, 2021</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2021</results_first_posted>
  <disposition_first_submitted>January 29, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 30, 2019</disposition_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01976728/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01976728/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 24 sites randomized subjects to the trial between April 2014 and February 2018. The trial sites that randomized subjects to the trial were: 22 in the United States of America and 2 in Canada.</recruitment_details>
      <pre_assignment_details>A total of 54 subjects were screened, of which 39 subjects were randomized. Of the 39 randomized subjects, 10 were randomized to LutrePulse 10 μg/pulse, 9 were randomized to LutrePulse 15 μg/pulse, 10 were randomized to LutrePulse 20 μg/pulse and 10 were randomized to placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LutrePulse 10 µg/Pulse</title>
          <description>Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="P2">
          <title>LutrePulse 15 µg/Pulse</title>
          <description>Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="P3">
          <title>LutrePulse 20 µg/Pulse</title>
          <description>Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject missed multiple doses of IMP</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) analysis set comprised all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>LutrePulse 10 µg/Pulse</title>
          <description>Gonadorelin acetate SC 10 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="B2">
          <title>LutrePulse 15 µg/Pulse</title>
          <description>Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="B3">
          <title>LutrePulse 20 µg/Pulse</title>
          <description>Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="4.20"/>
                    <measurement group_id="B2" value="29.6" spread="6.02"/>
                    <measurement group_id="B3" value="30.9" spread="5.67"/>
                    <measurement group_id="B4" value="29.5" spread="2.55"/>
                    <measurement group_id="B5" value="30.2" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.41" spread="6.065"/>
                    <measurement group_id="B2" value="23.70" spread="4.567"/>
                    <measurement group_id="B3" value="26.53" spread="4.218"/>
                    <measurement group_id="B4" value="23.85" spread="3.953"/>
                    <measurement group_id="B5" value="25.93" spread="5.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ovulation Rate</title>
        <description>Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).</description>
        <time_frame>From treatment Day 1 up to 4 weeks after second positive β-hCG test, approximately 9 weeks</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled</title>
            <description>Gonadorelin acetate SC 15 μg/pulse and SC 20 μg/pulse, administered via. OmniPod pump pooled</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Rate</title>
          <description>Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis compared the pooled ovulation rate of the LutrePulse 15 μg and 20 μg group to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses were tested using a stratified one-sided Fisher's exact test in the FAS including the randomization scheme as the stratification factor.</non_inferiority_desc>
            <p_value>0.0120</p_value>
            <p_value_desc>The SAS PROC FREQ with permutation-based Cochran-Mantel-Haenszel test with exact p-value derived from all possible permutations was employed for the calculation of p-value for the stratified Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>The success threshold at each analysis corresponded to a nominal p-value &lt;0.0130 to maintain an overall one-sided type I error rate of 0.025.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progesterone (P4) Levels</title>
        <description>Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.</description>
        <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled</title>
            <description>Gonadorelin acetate SC 15 μg/pulse and 20 μg/pulse, administered via. OmniPod pump pooled</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Progesterone (P4) Levels</title>
          <description>Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>P4 levels of the pooled LutrePulse 15 μg and 20 μg group were compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses were tested using a stratified one-sided Fisher's exact test in the FAS including the randomization scheme as the stratification factor.</non_inferiority_desc>
            <p_value>0.0553</p_value>
            <p_value_desc>The SAS PROC FREQ with permutation-based Cochran-Mantel-Haenszel test with exact p-value derived from all possible permutations was employed for the calculation of p-value for the stratified Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>The success threshold at each analysis corresponded to a nominal p-value &lt;0.0130 to maintain an overall one-sided type I error rate of 0.025.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.</description>
        <time_frame>2 to 4 weeks after a second positive serum β-hCG test</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled</title>
            <description>Gonadorelin acetate SC 15 μg/pulse and 20 μg/pulse, administered via. OmniPod pump pooled</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Clinical pregnancy rates of the pooled LutrePulse 15 μg and 20 μg group were compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses was tested using a stratified one-sided Fisher's exact test in the FAS including the randomization scheme as the stratification factor.</non_inferiority_desc>
            <p_value>0.0383</p_value>
            <p_value_desc>The SAS PROC FREQ with permutation-based Cochran-Mantel-Haenszel test with exact p-value derived from all possible permutations was employed for the calculation of p-value for the stratified Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>The success threshold at each analysis corresponded to a nominal p-value &lt;0.0130 to maintain an overall one-sided type I error rate of 0.025.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Pregnancy Rate</title>
        <description>Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.</description>
        <time_frame>Approximately 14 days after LH surge</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled</title>
            <description>Gonadorelin acetate SC 15 μg/pulse and SC 20 μg/pulse, administered via. OmniPod pump pooled</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Pregnancy Rate</title>
          <description>Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Biochemical pregnancy rates of the pooled LutrePulse 15 μg and 20 μg group were compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses were tested using a stratified one-sided Fisher's exact test in the FAS including the randomization scheme as the stratification factor.</non_inferiority_desc>
            <p_value>0.0246</p_value>
            <p_value_desc>The SAS PROC FREQ with permutation-based Cochran-Mantel-Haenszel test with exact p-value derived from all possible permutations was employed for the calculation of p-value for the stratified Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>The success threshold at each analysis corresponded to a nominal p-value &lt;0.0130 to maintain an overall one-sided type I error rate of 0.025.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LH Surge Detection</title>
        <description>Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.</description>
        <time_frame>Daily from Day 11 until first positive LH surge or until Day 39</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled</title>
            <description>Gonadorelin acetate SC 15 μg/pulse and 20 μg/pulse, administered via. OmniPod pump pooled</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>LH Surge Detection</title>
          <description>Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>LH surge detection of the pooled LutrePulse 15 μg and 20 μg group were compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses were tested using a stratified one-sided Fisher's exact test in the FAS including the randomization scheme as the stratification factor.</non_inferiority_desc>
            <p_value>0.0011</p_value>
            <p_value_desc>The SAS PROC FREQ with permutation-based Cochran-Mantel-Haenszel test with exact p-value derived from all possible permutations was employed for the calculation of p-value for the stratified Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>The success threshold at each analysis corresponded to a nominal p-value &lt;0.0130 to maintain an overall one-sided type I error rate of 0.025.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovarian Follicular Development: Number of Follicles With a Mean Diameter Greater Than or Equal to (≥)14 mm</title>
        <description>Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
        <time_frame>From treatment Day 10 to treatment Day 21</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
        </group_list>
        <measure>
          <title>Ovarian Follicular Development: Number of Follicles With a Mean Diameter Greater Than or Equal to (≥)14 mm</title>
          <description>Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>follicles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 10: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1344</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 10: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2726</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 10: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3173</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 12: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1275</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 12: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1088</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 12: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2374</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0796</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1757</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0584</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3711</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0143</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0060</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 21: Number of follicles with a mean diameter ≥14 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1573</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovarian Follicular Development: Number of Dominant Follicles With a Mean Diameter of ≥18 mm</title>
        <description>Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
        <time_frame>From treatment Day 10 to treatment Day 21</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Ovarian Follicular Development: Number of Dominant Follicles With a Mean Diameter of ≥18 mm</title>
          <description>Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>follicles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 12: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4142</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Number of follicles with a mean diameter ≥18 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2374</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2636</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4795</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3173</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3711</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4142</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 18: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 20 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0838</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 21: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 10 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3173</p_value>
            <p_value_desc>The p-value was based on the stratified (by randomization scheme) Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 21: Number of follicles with a mean diameter ≥18 mm in the LutrePulse 15 μg group was compared to placebo, using Wilcoxon's rank sum test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3778</p_value>
            <p_value_desc>The p-value was based on the Wilcoxon rank sum test without stratification.</p_value_desc>
            <method>Wilcoxon rank sum test</method>
            <method_desc>SAS PROC FREQ with modified ridit score (MODRIDIT option) was used for the stratified Wilcoxon rank sum test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteal Phase Support: Maximum P4 Levels</title>
        <description>Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
        <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod)</description>
          </group>
        </group_list>
        <measure>
          <title>Luteal Phase Support: Maximum P4 Levels</title>
          <description>Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.1" upper_limit="12.9"/>
                    <measurement group_id="O2" value="2.40" lower_limit="0.4" upper_limit="18.5"/>
                    <measurement group_id="O3" value="8.00" lower_limit="0.1" upper_limit="21.7"/>
                    <measurement group_id="O4" value="0.30" lower_limit="0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Maximum P4 levels in the LutrePulse 10 µg group were compared to placebo using an analysis of covariance (ANCOVA) model including the randomization scheme and treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6732</p_value>
            <p_value_desc>p-value for the LutrePulse 10 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>Least square mean (LSM) difference</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>7.87</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% confidence interval (CI) for the LutrePulse 10 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Maximum P4 levels in the LutrePulse 15 µg group were compared to placebo using an ANCOVA model including treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0814</p_value>
            <p_value_desc>p-value for the LutrePulse 15 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>LSM</param_type>
            <param_value>5.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>12.15</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% CI for the LutrePulse 15 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Maximum P4 levels in the LutrePulse 20 µg group were compared to placebo using an ANCOVA model including the randomization scheme and treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0223</p_value>
            <p_value_desc>p-value for the LutrePulse 20 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>LSM difference</param_type>
            <param_value>7.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>13.93</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% CI for the LutrePulse 20 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteal Phase Support: Mean P4 Levels</title>
        <description>Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
        <time_frame>Median post-dose P4 values across Treatment Days 19, 21, 23, 25, and 27</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, , administered via. OmniPod</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod)</description>
          </group>
        </group_list>
        <measure>
          <title>Luteal Phase Support: Mean P4 Levels</title>
          <description>Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.313" lower_limit="0.10" upper_limit="8.06"/>
                    <measurement group_id="O2" value="1.440" lower_limit="0.26" upper_limit="8.50"/>
                    <measurement group_id="O3" value="3.920" lower_limit="0.10" upper_limit="14.80"/>
                    <measurement group_id="O4" value="0.233" lower_limit="0.10" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean P4 levels in the LutrePulse 10 µg group were compared to placebo using an ANCOVA model including the randomization scheme and treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7355</p_value>
            <p_value_desc>p-value for the LutrePulse 10 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>LSM difference</param_type>
            <param_value>0.679</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.404</ci_lower_limit>
            <ci_upper_limit>4.762</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% CI for the LutrePulse 10 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean P4 levels in the LutrePulse 15 µg group were compared to placebo using an ANCOVA model including treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1980</p_value>
            <p_value_desc>p-value for the LutrePulse 15 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>LSM difference</param_type>
            <param_value>2.602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.444</ci_lower_limit>
            <ci_upper_limit>6.648</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% CI for the LutrePulse 15 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mean P4 levels in the LutrePulse 20 µg group were compared to placebo using an ANCOVA model including the randomization scheme and treatment group as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0187</p_value>
            <p_value_desc>p-value for the LutrePulse 10 µg group compared to placebo based on the fitted linear model were reported.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>PROC GLM was used for ANCOVA.</method_desc>
            <param_type>LSM difference</param_type>
            <param_value>4.880</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.878</ci_lower_limit>
            <ci_upper_limit>8.882</ci_upper_limit>
            <estimate_desc>The LSM difference on the treatment groups and 95% CI for the LutrePulse 20 µg group compared to placebo based on the fitted linear model were reported. Type III sum-of-squares for the LSMs were used for statistical comparisons.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Follicle-stimulating Hormone (FSH)</title>
        <description>FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10</description>
        <time_frame>Baseline (pre-dose), Treatment Day 1, Treatment Day 10</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Follicle-stimulating Hormone (FSH)</title>
          <description>FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FSH (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="5.40" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O3" value="2.70" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O4" value="0.10" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH (Day 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.8" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.3" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.7" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-0.01" lower_limit="-0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in FSH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 10 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8772</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in FSH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 15 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7805</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in FSH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 20 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6095</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LH</title>
        <description>LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10</description>
        <time_frame>Baseline (pre-dose), Treatment Day 1, Treatment Day 10</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LH</title>
          <description>LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="0.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="7.90" lower_limit="0.4" upper_limit="23.6"/>
                    <measurement group_id="O3" value="5.15" lower_limit="0.6" upper_limit="12.4"/>
                    <measurement group_id="O4" value="0.05" lower_limit="-0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.9" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.58" lower_limit="-1.7" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.03" lower_limit="-0.9" upper_limit="1.7"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in LH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 10 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1520</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in LH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 15 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0221</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in LH levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 20 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0316</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum FSH and LH Levels</title>
        <description>Mean FSH and LH levels on Day 1 and Day 10.</description>
        <time_frame>Treatment Days 1 and Day 10</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum FSH and LH Levels</title>
          <description>Mean FSH and LH levels on Day 1 and Day 10.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FSH (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="1.793"/>
                    <measurement group_id="O2" value="1.47" spread="1.112"/>
                    <measurement group_id="O3" value="2.48" spread="2.235"/>
                    <measurement group_id="O4" value="1.35" spread="1.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="4.010"/>
                    <measurement group_id="O2" value="6.20" spread="3.929"/>
                    <measurement group_id="O3" value="5.38" spread="2.565"/>
                    <measurement group_id="O4" value="1.52" spread="1.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH (Day 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.495"/>
                    <measurement group_id="O2" value="5.07" spread="2.530"/>
                    <measurement group_id="O3" value="5.24" spread="1.124"/>
                    <measurement group_id="O4" value="1.67" spread="1.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.669"/>
                    <measurement group_id="O2" value="0.27" spread="0.179"/>
                    <measurement group_id="O3" value="0.93" spread="0.954"/>
                    <measurement group_id="O4" value="0.73" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="9.507"/>
                    <measurement group_id="O2" value="8.82" spread="7.348"/>
                    <measurement group_id="O3" value="6.12" spread="3.745"/>
                    <measurement group_id="O4" value="0.79" spread="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH (Day 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="3.931"/>
                    <measurement group_id="O2" value="4.69" spread="2.692"/>
                    <measurement group_id="O3" value="4.07" spread="2.335"/>
                    <measurement group_id="O4" value="0.82" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol (E2) Serum Levels</title>
        <description>E2 serum levels on Day 1 and Day 10.</description>
        <time_frame>At treatment Day 1 and Day 10</time_frame>
        <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol (E2) Serum Levels</title>
          <description>E2 serum levels on Day 1 and Day 10.</description>
          <population>The full analysis set (FAS) comprised all randomized subjects who were included in ITT analysis set and had received at least 14 days of investigational medicinal product (IMP). One subject in the LutrePulse 10 µg/Pulse group was discontinued from the trial after 6 days exposure and is not included in the FAS (LutrePulse 10 µg/Pulse: n=9).</population>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.50" lower_limit="36.5" upper_limit="169.0"/>
                    <measurement group_id="O2" value="88.00" lower_limit="36.5" upper_limit="147.0"/>
                    <measurement group_id="O3" value="81.00" lower_limit="36.5" upper_limit="92.0"/>
                    <measurement group_id="O4" value="122.50" lower_limit="36.5" upper_limit="198.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 (pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.00" lower_limit="36.5" upper_limit="697.0"/>
                    <measurement group_id="O2" value="202.00" lower_limit="84.0" upper_limit="499.0"/>
                    <measurement group_id="O3" value="136.00" lower_limit="36.5" upper_limit="323.0"/>
                    <measurement group_id="O4" value="128.00" lower_limit="36.5" upper_limit="224.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in E2 levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 10 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3147</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>73.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.66</ci_lower_limit>
            <ci_upper_limit>218.65</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in E2 levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 15 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2290</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>95.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.01</ci_lower_limit>
            <ci_upper_limit>253.36</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change in E2 levels from Day 10 pre-treatment (prior to first dose) in the LutrePulse 20 μg/Pulse group was compared to placebo using an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5066</p_value>
            <p_value_desc>The p-value was derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM difference</param_type>
            <param_value>46.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-95.64</ci_lower_limit>
            <ci_upper_limit>189.61</ci_upper_limit>
            <estimate_desc>LSM difference and CIs were derived from an ANCOVA model with randomization scheme and treatment as factors and baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type, Intensity, and Frequency of Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.</description>
        <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
        <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Type, Intensity, and Frequency of Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.</description>
          <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematology, Clinical Chemistry, and Urinalysis</title>
        <description>Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.</description>
        <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
        <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, , administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology, Clinical Chemistry, and Urinalysis</title>
          <description>Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.</description>
          <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum chemistry (Sodium, &lt;=130 mmol/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis (Protein,mg/dL, -ve to +ve [post-dose])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis (Specific Gravity &lt;=1.005)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS)</title>
        <description>Proportion of subjects reporting OHSS classified as mild, moderate, or severe.</description>
        <time_frame>From treatment Day 1 to end-of-trial, approximately 10 weeks</time_frame>
        <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
        <group_list>
          <group group_id="O1">
            <title>LutrePulse 10 µg/Pulse</title>
            <description>Gonadorelin acetate SC 10 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O2">
            <title>LutrePulse 15 µg/Pulse</title>
            <description>Gonadorelin acetate SC 15 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O3">
            <title>LutrePulse 20 µg/Pulse</title>
            <description>Gonadorelin acetate SC 20 µg/pulse as fixed dose, administered via. OmniPod pump</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS)</title>
          <description>Proportion of subjects reporting OHSS classified as mild, moderate, or severe.</description>
          <population>The safety analysis set comprised all randomized subjects who received at least one pulsatile delivery of IMP. The number count is based on the actual treatment subjects received: one subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent AEs (TEAEs) occurred after the start of IMP administration and within 5 days after the last dose, or a pre-treatment AE or pre-existing medical conditioning the worsened in intensity after the start of IMP and within 5 days after the last dose</time_frame>
      <desc>TEAEs were defined as AEs that occurred after the start of IMP administration and within 5 days after the last dose.&#xD;
All subjects who received at least one pulsatile injection delivery of IMP were included in safety analysis set and were analyzed according to the actual treatment received. One subject randomized to LutrePulse 15 µg/Pulse had received placebo and was moved to the placebo group in the safety analysis set (LutrePulse 15 µg/Pulse: n=8, Placebo: n=11).</desc>
      <group_list>
        <group group_id="E1">
          <title>LutrePulse 10 µg/Pulse</title>
          <description>Gonadorelin acetate SC 10 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="E2">
          <title>LutrePulse 15 µg/Pulse</title>
          <description>Gonadorelin acetate SC 15 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="E3">
          <title>LutrePulse 20 µg/Pulse</title>
          <description>Gonadorelin acetate SC 20 µg/pulse as a fixed dose, administered via. OmniPod pump</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal distesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <phone>+1 833-548-1402</phone>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

